TY -的T1 - nintedanib的疗效re not influenced by emphysema in the INPULSIS trials JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01655-2018 VL - 53 IS - 4 SP - 1801655 AU - Cottin, Vincent AU - Azuma, Arata AU - Raghu, Ganesh AU - Stansen, Wibke AU - Stowasser, Susanne AU - Schlenker-Herceg, Rozsa AU - Kolb, Martin Y1 - 2019/04/01 UR - //www.qdcxjkg.com/content/53/4/1801655.abstract N2 - Emphysema is a common comorbidity in patients with idiopathic pulmonary fibrosis (IPF) [1–4]. Due to the combination of restrictive and obstructive effects, patients with concomitant IPF and emphysema typically present with normal or elevated forced vital capacity (FVC) but reduced diffusing capacity [5]. Data from retrospective studies have demonstrated that lung function decline is attenuated in patients with IPF who have emphysema [6], with some evidence suggesting a threshold for extent of emphysema beyond which FVC decline is reduced [7].In post hoc analyses of pooled data from the INPULSIS trials, the treatment effect of nintedanib versus placebo was not influenced by the presence of emphysema (yes versus no) or by FEV1/FVC ratio (≥0.7 to ≤0.8 versus >0.8) at baseline http://ow.ly/Gmwn30nwPY1The authors acknowledge the contribution of David M. Hansell, formerly of the Department of Radiology, Royal Brompton and Harefield NHS Foundation Trust, London, UK, for reading the HRCT scans in the INPULSIS trials. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Julie Fleming and Wendy Morris of FleishmanHillard Fishburn, Ltd., London, UK, during the preparation of this article. The authors were fully responsible for all content and editorial decisions, were involved in all stages of manuscript development, and approved the final version. ER -